DescriptionProfound Medical Corp is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. The company is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. It is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.
Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.
A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.
What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.
A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.
Latest Press Releases
|Period||Period Low||Period High||Performance|
|1-Month|| 19.25 +6.03% increase |
| 25.45 -19.80% decrease |
| -4.76 (-18.91%) decrease |
|3-Month|| 19.25 +6.03% increase |
| 34.11 -40.16% decrease |
| -12.90 (-38.73%) decrease |
|52-Week|| 15.43 +32.27% increase |
| 36.73 -44.43% decrease |
| +3.43 (+20.20%) increase |